Carl Power
Carl Power
Sten Madsbad
Sten Madsbad
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial [0.03%]
利拉鲁肽对2型糖尿病男性患者性功能影响的探索性分析：REWIND安慰剂对照随机试验结果
Harpreet S Bajaj,Hertzel C Gerstein,Purnima Rao-Melacini et al.
Harpreet S Bajaj et al.
Background: Diabetes is a major risk factor for erectile dysfunction, however, the effect of GLP-1 receptor agonists on erectile dysfunction is unknown. We aimed to assess the incidence, prevalence, and progression of ere...
Randomized Controlled Trial
The lancet. Diabetes & endocrinology. 2021 Aug;9(8):484-490. DOI:10.1016/S2213-8587(21)00115-7 2021
Ray Cavanaugh
Ray Cavanaugh
First, do no harm [0.03%]
首先，不伤害病人
Jennifer Thorley
Jennifer Thorley
Targeting RET-mutated thyroid and lung cancer in the personalised medicine era [0.03%]
RET突变的甲状腺癌和肺癌在个体化医学时代的治疗策略
Joanna Klubo-Gwiezdzinska
Joanna Klubo-Gwiezdzinska
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study [0.03%]
转染重排(RET)基因变异的晚期或转移性甲状腺癌患者的普拉曲塞(Pralsetinib)(ARROW):一项多队列、开放标签、注册、Ib/II期临床试验
Vivek Subbiah,Mimi I Hu,Lori J Wirth et al.
Vivek Subbiah et al.
Background: Oncogenic alterations in RET represent important therapeutic targets in thyroid cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent, selective RET inhibitor, in patien...